News

HDA UK MEDIA AND POLITICAL BULLETIN – 20 July 2017

MEDIA SUMMARY 

C+D’s open letter to new pharmacy minister Steve Brine
Chemist and Druggist, James Waldron, 19 July 2017

In an open letter, Chemist and Druggist congratulated the newly appointed minister while also making clear that pharmacies felt “undermined by their own government”. C+D criticized the recent cuts as being overly harsh, and laid out three changes that could be made to better support the pharmacy industry:
1. Pursue a funding model that is “fair, realistic and sustainable”.
2. Embrace legal changes that reform the legal framework around dispensing errors.
3. Work with pharmacists and the National Pharmacy Association to fulfill the 2017 manifesto commitment to better integrate pharmacies into the wide healthcare system.

MHRA continues to regulate in run-up to Brexit
The Pharmaceutical Journal, Debbie Andalo, 19 July 2017

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed its continuing role in regulating medicines in the run-up to Brexit. The MHRA also continues to respond to regulatory inquiries and notices from the European Medicines Agency. As the MHRA has recently noted, “until the exit negotiations are concluded, the UK remains a full member of the EU and all the rights and obligations of of EU membership remain in force.” The MHRA is currently working closely with the government to analyse the impact of Brexit and develop a regulatory framework post-leaving.

Arvato Systems signs deal with SecurMed UK to deliver medicines verification
The European Pharmaceutical Journal, Steve Bremer, 19 July 2017

The EPJ reported on the recent press release announcing the Arvato and SecurMed collaboration. First reported in this update yesterday, Arvato and SecurMed are collaborating to implement the UK’s Medicines Verification System. SecurMed is the not-for-profit organization responsible for implementation, while Avarto is an IT company that is helping companies transform their digital offerings and regulatory systems.

China slashes prices of patented western drugs by up to 70%
The Financial Times, Tom Hancock and Wang Xueqiao, 19 July 2017

China has slashed the prices for a number of top brand-name drugs by as much as 70%. Thirty-six brand-name drugs, mainly developed by overseas companies, will see average price cuts of 44%. The regulatory changes make medicines eligible for co-payment, bringing them into the reach of more consumers. China is the world’s second largest pharmaceutical market. Cancer is becoming a major concern in China, and drugs designed to tackle it have seen the steepest reductions. Roche’s anti-breast cancer drug saw price reductions of 67%. Almost all drugs that saw their prices drops are still patent protected, sending a signal that China will be more open to seeing Western companies in the pharmaceutical market.

July 2017 Retail Report – GIRP
GIRP, 18 July 2017

The European Healthcare Distribution Association (GIRP) has released it’s July retail report, covering both international and domestic news. On the international front, it notes the growing use of big data, and asks whether it is the future of the industry. In the United Kingdom, it notes that the Care Quality Commission (CQC) has raised concerns about the quality of care delivered by online pharmacies, saying they do not do enough to ensure that what patients order “is appropriate”. This follows developments in Germany, which has not seen an increase in mail-order pharmaceuticals – with in-person pharmacies driving sales.

PARLIAMENTARY COVERAGE

There is no parliamentary coverage.

 

PARLIAMENTARY COVERAGE

There is no parliamentary coverage.

FULL COVERAGE 

Arvato Systems signs deal with SecurMed UK to deliver medicines verification
The European Pharmaceutical Journal, Steve Bremer, 19 July 2017

SecurMed UK, the UK Medicines Verification Organisation, is entering into a Letter of Intent with Arvato Systems as its IT blueprint service provider.

In a joint statement, SecurMed UK and Arvato Systems said they were looking forward to “working together to enable the UK medicines supply and healthcare sectors to successfully implement the UK Medicines Verification System by 9 February 2019”.

​​​The UK is one of the largest and most complex markets for medicines supply within Europe and the appointment of Arvato Systems represents a significant milestone in the UK’s journey to meet its obligations under the Falsified Medicines Directive and associated Delegated Regulation, according to the statement.

SecurMed UK is the not-for profit organisation that will manage the UK Medicines Verification System under the supervision of the UK national competent authorities – MHRA and Department of Health. SecurMed UK has been incorporated by the principal supply chain stakeholder associations (Association of British Pharmaceutical Industry (ABPI), British Generic Manufacturers Association (BGMA), British Association of European Pharmaceutical Distributors (BAEPD), Healthcare Distribution Association (HDA), National Pharmacy Association (NPA) and Company Chemists’ Association (CCA)) as required by the Falsified Medicines Directive.

Global IT specialist Arvato Systems supports major companies through digital transformation. It develops innovative IT solutions, transitions its clients into the Cloud, integrates digital processes and take on IT systems operation and support.​ In Healthcare, Arvato Systems provides its own serialisation solutions covering the entire end-to-end process chain that support both individual producers and national verification systems. It was chosen as an official service provider by the European Medicines Verification Organization (EMVO).

MHRA continues to regulate in run-up to Brexit
The Pharmaceutical Journal, Debbie Andalo, 19 July 2017

The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed its continuing role in regulating medicines safety while the Brexit negotiations continue.

The UK drugs regulator took the step in response to the public statement made earlier this month (4 July) by health secretary Jeremy Hunt and business secretary Greg Clark, confirming the UK government’s desire “to retain a close working partnership in aspects of medicines regulation after the UK leaves the EU in the interest of public health and safety”.

The two secretaries of state wrote to the Financial Timesoutlining three principles that would underpin the challenge of developing a new regulatory system post-Brexit. The MHRA was also responding to notices issued by the European drugs safety regulator — the European Medicines Agency (EMA) — and the Human Coordination Group for Mutual Recognition and Decentralised Procedures, the body which helps to resolve any differences in marketing authorisation data involving two or more European Union (EU) member states.

The notices highlight issues that marketing authorisation holders should be considering as the UK begins talks to leave the EU, and they include an EMA question and answer document for pharmaceutical companies published by the EMA in May.

In its statement published on 17 July, the MHRA said: “Until the exit negotiations are concluded, the UK remains a full member of the EU and all the rights and obligations of EU membership remain in force.

HDA UK MEDIA AND POLITICAL BULLETIN – 20 July 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?